**Epidemiology and associated factors of irritable bowel syndrome in an Andean community from Peru**

Epidemiología y factores asociados del síndrome del intestino irritable en una comunidad andina del Perú

Claudia Mariella Alvizuri Gómez¹, Álvaro Bellido Caparó¹, Frine Samalvides Cuba², José Luis Pinto Valdivia¹

¹ Department of Gastroenterology, Hospital Nacional Cayetano Heredia. Lima, Peru.
² Department of Tropical and Infectious Diseases, Hospital Nacional Cayetano Heredia. Lima, Peru.

Recibido: 04/02/2021 - Aprobado: 01/03/2021

ORCID: Claudia Alvizuri Gómez: https://orcid.org/0000-0003-0833-7997, Álvaro Bellido Caparó: https://orcid.org/0000-0002-7710-0662,
Frine Samalvides Cuba: https://orcid.org/0000-0001-6782-2488, José Pinto Valdivia: https://orcid.org/0000-0001-6570-9537

**ABSTRACT**

Introduction: Irritable bowel syndrome (IBS) is a chronic functional bowel condition with an average world prevalence of 11.2%. It is associated with multiple factors as female sex, young age, stress, anxiety and depression which can have a negative impact on quality of life. IBS in Peru is not investigated at all specially in the Andean region. The objective of this study is to determine the prevalence and associated factors of IBS in an Andean community from Peru using the Rome IV criteria.

Materials and methods: Cross-sectional study in a rural community dedicated to livestock and agriculture in Peru at 3,235 meters above sea level. Questionnaires provided by the Rome Foundation as the Rome IV – Diagnostic questionnaire for adults, Irritable Bowel Syndrome - Symptom Severity Scale and Bristol stool scale were used. Results: 130 residents met the inclusion criteria. 46.9% were males with an average age of 54 years old. 11.54% presented red flags and were not included in the analysis. 13.1% were diagnosed with IBS and 52.9% presented constipation as predominant bowel pattern. 52.9% presented a mild course of the disease. In the chi-square analysis, factors as depression, anxiety, female sex, younger age, liquefied petroleum gas exposure for cooking and education achievement were statistically significant associated to IBS. In the logistic regression analysis, anxiety was the unique independent predictor factor with an OR of 9.6 (95% IC: 1.78-51.82). Conclusion: IBS is a prevalent condition in the Andean region and should be managed as a public health issue to improve quality of life.

Keywords: Irritable bowel syndrome; Prevalence; Anxiety; Peru (source: MeSH NLM).

**RESUMEN**

Introducción: El síndrome del intestino irritable (SII) es una enfermedad intestinal funcional crónica con una prevalencia mundial promedio del 11.2%. Se asocia a múltiples factores como el sexo femenino, la juventud, el estrés, la ansiedad y la depresión que pueden tener un impacto negativo en la calidad de vida. El SII en Perú, no es investigado a profundidad; especialmente en la región andina. El objetivo de este estudio es determinar la prevalencia y factores asociados del SII en una comunidad andina de Perú utilizando los criterios de Roma IV. Materiales y métodos: Estudio transversal en una comunidad rural dedicada a la ganadería y la agricultura en Perú a 3 235 metros sobre el nivel del mar. Se utilizaron cuestionarios proporcionados por la Fundación de Roma como el Rome IV – Cuestionario de diagnóstico para adultos, Síndrome del intestino irritable - Escala de gravedad de los síntomas y Escala de heces de Bristol. Resultados: 130 residentes cumplieron los criterios de inclusión. 46.9% fueron varones con una edad media de 54 años. El 11.54% presentó señales de alerta y no fueron incluidos en el análisis. El 13.1% fueron diagnosticados con SII y el 52.9% presentó estreñimiento como patrón intestinal predominante. El 52.9% presentó un curso leve de la enfermedad. En el análisis de chi-cuadrado, factores como depresión, ansiedad, sexo femenino, edad más joven, exposición a gas licuado de petróleo para cocinar y logros educativos fueron estadísticamente significativos asociados con el SII. En el análisis de regresión logística, la ansiedad fue el único factor predictor independiente con una OR de 9.6 (IC del 95%: 1.78-51.82). Conclusión: El SII es una condición prevalente en la región andina y debe ser manejado como un problema de salud pública para mejorar la calidad de vida.

Palabras clave: Síndrome del colon irritable; Prevalencia; Ansiedad; Perú (fuente: DeCS BIREME).

**INTRODUCTION**

Irritable bowel syndrome (IBS), is a chronic functional bowel condition with an international prevalence of 11.2% but a range that can vary between 10-21% around the world, depending on the surveyed population and diagnostic test used¹⁻³.

It is one of the most prevalent diseases diagnosed in the gastroenterological practice and can have a negative impact in the quality of life and economy of the patient. Therefore, its understanding, diagnosis, and treatment is fundamental for clinical improvement⁴⁻⁵.
Many authors have tried to identify the associated factors for its occurrence. Female sex, young age, familiar history, gastrointestinal infection, stress, depression and anxiety have been identified as determinants for its appearance. However, new determinants as environmental pollutants, radiation and bacterial contamination are emerging as new factors that can trigger the development of IBS.

IBS in Peru is a prevalent condition but not investigated at all. Little literature exists about its prevalence, being stipulated between 15% and 22% using the Rome III criteria and the Maning score respectively. After this data, no more studies were performed using the new Rome IV criteria provided by the Rome Foundation.

These studies were performed in the coast and Amazon regions in Peru. However, no research has been performed in the Peruvian Andes. Conditions like high indoor air pollution from cooking with biomass fuels, depression-anxiety and higher prevalence of gastrointestinal infections could suggest a higher rate of IBS.

The aim of this study is to determine the prevalence and associated factors of IBS in an Andean community from Peru using the Rome IV criteria.

MATERIALS AND METHODS

We conducted a cross-sectional study in a rural Andean community named Ayavírí in Lima - Peru, located at 3,235 meters above sea level. This community is dedicated to agriculture and livestock. As cooking fuels resources, biomass and liquefied petroleum gas (LPG) are used. According to the last demographic census taken place in 2017, 665 people lived in this town and only those who met the inclusion criteria as residents over 18 years old were considered eligible for this study. Participants were excluded from the study if they were under 18 years old or did not live permanently in Ayavírí considered as less than 11 months in a year. Before fulfilling the Irritable Bowel Syndrome criteria, alarm features like unexplained weight loss, gastrointestinal blood loss, documented anemia, dysphagia, severe vomiting, first-degree family history of gastrointestinal cancer diagnosis and abdominal surgery of any type were registered. If the interviewed presented any alarm feature, no IBS diagnosis was made and urgent referral to a hospital was indicated.

The data was collected to the entire population by physicians who went house by house approaching all the residents in Ayavírí. Written questionnaires provided by the Rome Foundation as the Rome IV – Diagnostic questionnaire for adults, Irritable Bowel Syndrome – Symptom Severity Scale and Bristol stool scale were used. Additionally, data regarding age, sex, diet, smoking habit, alcohol consumption, and levels of anxiety and depression though the Hospital Anxiety Depression Scale validated for community surveys were collected. Exposure to biomass and LPG, were categorized using the “biomass exposure index”, which is calculated as number of hours exposed to biomass per day multiplied by years of cooking, and “gas exposure index” in case of exposure to LPG.

Written informed consent was obtained from all study participants. The study was approved by the Institutional Committee for Research Ethics in Humans by the Peruvian University Cayetano Heredia (Lima, Peru) with the approval number 739-29-19.

Before data analysis, we examined the distribution of the variables and outcomes of interest. Data analysis was processed using STATA version 16.0.

RESULTS

During the survey, 130 residents met the inclusion criteria. 46.9% were males, and 53.1% were females. The average age of interviewed participants was 54 years old with a minimum of 18 and a maximum of 93 years old. 48.5% presented a body mass index within normal values while 43.8% were overweight. Demographic data of the population is described in Table 1.

Among all the participants 15 (11.54%) presented alarm features and most of them had no previous evaluation by a physician. Out of the 130 participants, 5 (3.9%) presented blood in stools, 6 (4.6%) documented anemia without further evaluation, 1 (0.8%) persistent vomiting, 6 (4.6%) inexplicable weight loss, 1 (0.8%) first-degree family history of gastrointestinal cancer and current symptoms. 8 participants had previous abdominal surgery so were no considered in the final analysis for diagnosis of IBS due to concerns of symptoms being consequence of previous surgeries.

Natural herbs as infusion drinks were consumed by 97.7% of the people surveyed. 93.1% consumed these daily, 58.5% enhanced their consumption when symptoms being consequence of previous surgeries.

Among the natural herbs consumed by the population, *Minthostachys mollis* known by the common name Muña was the most ingested (67.69%), followed by Chamomile (43.85%), Epazote (21.54%), Lemon balm (21.54%) and *Bidens pilosa* (9.23%).

IBS was present in 13.1% of which 52.9% presented a mild severity score and 41.2% a moderate score.
In the analysis of fuels types used for cooking, 73 (56.2%) participants were exposed only to biomass, 7 (5.4%) only to LPG, and 50 (38.4%) to both fuels. The biomass exposure index was lower in participants who used biomass and LPG vs. only biomass (72.7 vs. 105.2; p = 0.001). Gas (LPG) exposure index was higher in the only LPG vs. both types of fuels (56 vs 8.7; p < 0.001). The average age in the only biomass group was 59.05 years old vs. 40.43 in the only LPG group (p=0.01). 57.1% of female participants were identified in the only LPG group vs. 45.2% in the only biomass group.

Only 1 resident reported a severe presentation of IBS (Table 2).

In the chi-square and T student analysis, IBS was significant for depression, anxiety, female sex, age, education achievement and LPG exposure with a p value <0.05 (Table 3).

| Table 1. Demographic data. | n (%) |
|----------------------------|-------|
| **Sex**                    |       |
| Male                       | 61 (46.9) |
| Female                     | 69 (53.1) |
| **BMI (Body mass index)**  |       |
| <18                        | 0 (0)  |
| 18-24.9                    | 63 (48.5) |
| 25-29.9                    | 57 (43.8) |
| 30-34.9                    | 10 (7.7)  |
| >35                        | 0 (0)  |
| **Education achievement**  |       |
| 1. Illiterate              | 6 (4.6)  |
| 2. Incomplete elementary school | 28 (21.5) |
| 3. Complete elementary school | 36 (27.7) |
| 4. Incomplete high school  | 9 (7)   |
| 5. Complete high school    | 44 (33.8) |
| 6. Technical career        | 6 (4.6)  |
| 7. University postgraduate | 1 (0.8)  |
| Age                        |       |
| 18-29 years                | 13 (10) |
| 30-59 years                | 68 (52.3) |
| 60-79 years                | 35 (26.9) |
| > de 80 years              | 14 (10.8) |
| **Coca leaf chewing**      |       |
| Yes                        | 7 (5.4)  |
| No                         | 123 (94.6) |
| **Tobacco**                |       |
| Yes                        | 0 (0)  |
| No                         | 130 (100) |
| **Alcohol consumption**    |       |
| No                         | 82 (63.1) |
| Yes                        | 48 (36.9) |
| 4 drinks per day           | 0 (0)  |
| 2 - 3 drinks per day       | 0 (0)  |
| 1 drink per day            | 8 (16.7) |
| Less than 1 drink per day  | 40 (83.3) |
| **Red flags**              |       |
| No                         | 115 (88.46) |
| Yes                        | 15 (11.54) |
| Bloody stools              | 5 (3.85) |
| Documented anemia without further evaluation | 6 (4.62) |
| Persistent vomiting        | 1 (0.77) |
| Unintentional weight loss  | 6 (4.62) |
| 1° degree relative under 50 years with GI cancer | 1 (0.77) |
| Dysphagia                  | 0 (0)  |

| Table 2. Prevalence of irritable bowel syndrome and severity score. | n (%) |
|---------------------------------------------------------------------|-------|
| Irritable bowel syndrome                                            |       |
| Yes                                                                  | 17 (13.1) |
| No                                                                   | 113 (86.9) |
| **Bristol stool scale in Irritable Bowel Syndrome patients**        |       |
| Mostly constipation                                                  | 9 (52.9) |
| Mostly diarrhea                                                      | 2 (11.8) |
| Mixed                                                                | 6 (35.3) |
| **Severity Score Irritable Bowel Syndrome**                         |       |
| Mild                                                                 | 9 (52.9) |
| Moderate                                                             | 7 (41.2) |
| Severe                                                               | 1 (5.9)  |

| Table 3. Chi square analysis. | IBS + (17) | IBS – (113) | p value |
|--------------------------------|------------|------------|---------|
| Depression                     | 12 (70.59%)| 23 (20.35%)| 0.000   |
| Anxiety                        | 12 (70.59%)| 15 (13.27%)| 0.000   |
| Female sex                     | 13 (76.47%)| 56 (49.56%)| 0.038   |
| Medication intake in the last 12 months | 5 (29.41%) | 56 (49.56%) | 0.121 |
| Age (mean)                     | 43.88      | 55.70      | 0.013   |
| Height (mean)                  | 1.55       | 1.57       | 0.394   |
| BMI (body mass index)          | 25.63      | 25.00      | 0.377   |
| Education achievement          | 6.45       | 5.46       | 0.012   |
| Gastrointestinal infection during the last year | 7 (41.18) | 37 (32.74) | 0.493 |
| Biomass index exposure (mean)  | 69.38      | 88.73      | 0.179   |
| Gas (LPG) exposure index (mean)| 13.05      | 5.54       | 0.05    |
| Alcohol consumption            | 5 (29.4%)  | 43 (38.05%)| 0.491   |
| Coca leaf chewing              | 0 (0%)     | 7 (6.2%)   | 0.291   |
Logistic regression was performed for obtaining Odds Ratio (OR) values. Only anxiety was statistically significant with an OR of 9.6 (95% confidence interval: 1.78-51.82). We could not be able to demonstrate association between biomass exposure, or LPG use and IBS (Table 4).

**DISCUSSION**

Irritable bowel syndrome can have a detrimental quality of life in the patient if it is not recognized nor treated. The prevalence of IBS in our study was 13.1%, a percentage almost similar to the general worldwide population (1). None of these patients was diagnosed with IBS before and was not receiving treatment at that moment. The majority of participants reported a predominance of constipation over diarrhea as a bowel pattern in IBS. This has been demonstrated in other Latin American studies in which constipation predominance is more prevalent than diarrhea in contrast to European and Asian regions (20,21).

Few studies have addressed this situation in Peru. Gonzales, et al evaluated the prevalence of IBS in a coastal area of northern Peru. 15% of surveyed residents fulfilled the Rome III criteria for IBS being female in majority. In this study no association was found between gender and presence of IBS in contrary to our study in which we identified a statistically significant difference (10). Curioso et al., performed a prevalence study in the jungle region. They evaluated 231 people randomly selected and applied two tests: Manning and Dyspepsia test. IBS was identified in 22.0% of the population and was associated with dyspepsia (11). Prevalence of IBS in minority Peruvian groups as medicine students has also being analyzed and revealed a prevalence of 12.4%, however this result cannot be extrapolated to the general population (22).

The difference in the prevalence of IBS in our study in comparison with the first two studies described before, could be attributed to the different characteristic of the surveyed population and the use of the new Rome IV criteria which have demonstrated to have a likelihood ratio of 4.82 compared to 2.45 with Rome III and higher values for sensitivity (62.7%) and specificity (97.1%) (23,24).

Out of the total participants, 11.54% presented red flags and most of them did not complete their medical evaluations in the past due to difficulties to access to medical care.

In the chi-square analysis, IBS was associated with depression and anxiety. The association between psychological disorders and functional bowel disorders has been widely demonstrated in multiple studies, and prompt identification and treatment help in the management of this disorder (25). More female participants were statistically significant associated with IBS, another association widely identified with a ratio of 2-2.5:1 in patients who seek medical care (26,27).

No statistically significant difference was found in relation to biomass index exposure; however, a higher exposure to LPG and higher education achievement was statistically significant in the IBS group. We could observe that those who were exposed only to LPG, were younger and female in relation to those exposed only to biomass. All factors associated to IBS (28,29).

As an analytical cross-sectional study, our limitation is that we cannot determine a causal relationship. More studies in this field are required in order to evaluate the impact of different factors in the development of IBS.

In conclusion, the prevalence of IBS in the community surveyed was of 13.1% and factors as depression, anxiety, female sex, younger age, LPG exposure and higher education achievement were statistically significant associated. IBS is a prevalent condition in the Andean region and should be managed as a public health issue to improve quality of life of residents as well as encourage early detection of red flags and improve health care access.

**Disclosure of conflicts of interest:** None to declare by none of the authors.

**Funding:** None

**REFERENCES**

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21. e4. doi: 10.1016/j.cgh.2012.02.029.

2. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004;54(504):495-502.
Epidemiology of irritable bowel syndrome in Peru

Alvizuri Gómez CM, et al.

1. Siah KTH, Wong RK, Chan YH, Ho KY, Gwee K. Prevalence of Irritable Bowel Syndrome in Singapore and Its Association with Dietary, Lifestyle, and Environmental Factors. J Neurogastroenterol Motil. 2016;22:670-6. doi: 10.5056/jnm15148.

2. Lacy BE, Mearin F, Chang L, Chevy WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-407. doi: 10.1053/j.gastro.2016.02.031.

3. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122(6):1701-14. doi: 10.1053/gast.2002.33741.

4. Choghakhori R, Abbasnezhad A, Amani R, Alipour M. Sex-Differences in Clinical Symptoms, Quality of Life, and Biochemical Factors in Irritable Bowel Syndrome. Dig Dis Sci. 2017;62(6):1550-60. doi: 10.1007/s10620-017-5546-6.

5. Lee C, Doo E, Choi JM, Jang SH, Ryu HS, Lee JY, et al. The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis. J Neurogastroenterol Motil. 2017;23(3):349-62. doi: 10.5056/jnm16220.

6. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009;15(29):3591-6. doi: 10.3748/wjg.15.3591.

7. Marynowski M, Likofskas A, Zatorski H, Fichna J. Role of environmental pollution in irritable bowel syndrome. World J Gastroenterol. 2015;21(40):11371-8. doi: 10.3748/wjg.v21.40.11371.

8. Gonzales Camarra RG, Ruiz Sánchez JC, León Jiménez F, Cosio Vargas JG, Rojas Medina LM, et al. Lesiones de intestino irritable en una comunidad de la Selva Peruana. Rev Gastroenterol Peru. 2005;25(3):140-7. doi: 10.1111/j.1572-0241.2004.40188.x.

9. Mengual MA, Frutos-Ferriz R, Valero-Caballero ML, et al. Environmental pollution in irritable bowel syndrome. World J Gastroenterol. 2002;8(6):1287-91. doi: 10.3748/wjg.15.3591.

10. Mansouri A, Rarani MA, Fallahi M, Alvandi I. Irritable bowel syndrome has origins in the childhood socioeconomic environment. Am J Gastroenterol. 2004;99(8):1572-8. doi: 10.1111/j.1572-0241.2004.40188.x.

11. Cabrera A, Carrasco A, Cipriano J. Impacto en la salud del uso de biocombustibles en el interior de las viviendas de la comunidad nativa de Lamas, San Martín, Perú. Parásitol latinoam. 2003;58(1-2):35-40. doi: 10.4067/S0717-77122003000100006.

12. Boeckxstaens GE, Drug V, Dumitrascu D, Farmer AD, Hamdy N, Hamdani N, et al. Phenotyping of subjects for large scale studies on patients with IBS. Neurogastroenterol Motil. 2014;26(4):651-60. doi: 10.1111/nmm.2014.04502.x.

13. Palsson OS, Whitehead WE, van Tilburg MA, Chung L, Chey W, Crowell MD, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. 2016;150(6):1481-91. doi: 10.1053/j.gastro.2016.02.014.

14. Fone G, Loundou A, Hamdani N, Bokouaci W, Dargel A, Oliveira J, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651-60. doi: 10.1007/s00406-014-04502-z.

15. Black CJ, Craig O, Dixon J, Ford AC. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 2021;70(6):1110-6. doi: 10.1136/gutjnl-2020-322519.

16. Behera D, Jindal SK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest. 1991;100(2):385-8. doi: 10.1378/chest.100.2.385.

17. Mahesh PA, Jayaraj BS, Prabhakar AK, Chaya SK, Vijayshima R. Identification of a threshold for biomass exposure index for chronic bronchitis in rural women of Mysore district, Karnataka, India. Indian J Med Res. 2013;137(1):87-94.

18. Gerson CD, Gerson MJ, Awad RA, Chowdhury A, Dancey C, Poitras P, et al. Irritable bowel syndrome: an international study of symptoms in eight countries. Eur J Gastroenterol Hepatol. 2008;20(7):639-67. doi: 10.1097/MEG.0b013e328253a24.

19. Gómez Alvarez DE, Morales Vargas JG, Rojas Medina LM, Mújica Oviedo SC, Camacho López PA, Rueda Jaimes CE. Factores sociosanitarios y prevalencia del síndrome del intestino irritable según los criterios diagnósticos de Roma III en una población general de Colombia. Gastroenterol Hepatol. 2009;32(6):395-400. doi: 10.1101/j.gastrohep.2009.01.177.

20. Vargas-Matos I, Ng-Sueng LF, Flores-Arriaga J, Beltrán-Flores S, Lema-Correa M, Piscoya A, et al. Superposición del síndrome de intestino irritable y dispepsia funcional basados en criterios ROMA III en estudiantes de medicina de una universidad privada de Lima, Perú. Rev Gastroenterol Peru. 2015;35(3):219-25.

21. Vargas-Matos I, Ng-Sueng LF, Flores-Arriaga J, Beltrán-Flores S, Lema-Correa M, Piscoya A, et al. Superposición del síndrome de intestino irritable y dispepsia funcional basados en criterios ROMA III en estudiantes de medicina de una universidad privada de Lima, Perú. Rev Gastroenterol Peru. 2015;35(3):219-25.

22. Black CJ, Craig O, Davie J, Ford AC. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 2021;70(6):1110-6. doi: 10.1136/gutjnl-2020-322519.

23. Palsson OS, Whitehead WE, van Tilburg MA, Chung L, Chey W, Crowell MD, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. 2016;150(6):1481-91. doi: 10.1053/j.gastro.2016.02.014.

24. Bond G, Loundou A, Hamdani N, Bokouaci W, Dargel A, Oliveira J, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651-60. doi: 10.1007/s00406-014-04502-z.

25. Böeckxstaens GE, Drug V, Dumitrascu D, Farmer AD, Hamer J, Hausken T, et al. Phenotyping of subjects for large scale studies on patients with IBS. Neurogastroenterol Motil. 2016;28(8):1134-47. doi: 10.1111/nmm.12886.

26. Kim YS, Kim N. Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(4):544-58. doi: 10.5056/jnm18082.

27. Mansouri A, Ranjani MA, Fallahi M, Alvandi I. Irritable bowel syndrome is concentrated in people with higher educations in Iran: an inequality analysis. Epidemiol Health. 2017;39:e2017005. doi: 10.4178/eph.2017005.

28. Moraes BF, Moraes RA, Godoy C, Moraes CA, Moraes SK. Breath hydrogen test in patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18(9):1393-8. doi: 10.5056/jnm15148.